JENSCARE-B (09877) announced its annual results for the period ending December 31, 2025. During the reporting period, the company continued to advance the global commercialization strategy for its interventional structural heart disease products. The group recorded revenue of RMB90.6 million, along with other income and gains of RMB16.6 million, bringing the total to RMB107 million.
The year 2025 marked the first full year of the company’s commercial operations. Throughout the period, JENSCARE-B remained focused on interventional structural heart products and steadily implemented its internationalization strategy, accelerating the global value conversion of its differentiated core technologies.
The company’s aortic valve replacement product, Ken-Valve, achieved rapid sales and implantation growth in its first commercial year. Multiple key products, including the tricuspid valve replacement device LuX-Valve Plus and the mitral valve repair clip JensClip, achieved clinical and commercial breakthroughs in numerous countries and regions worldwide.
Generating significant revenue in its inaugural commercial year reflects the strong commercialization capabilities of the company’s team. As international operations continue to deepen, JENSCARE-B expects to achieve steady and rapid revenue growth, laying a solid foundation for long-term sustainable development.
Innovation remains a core pillar of the company’s strategy. JENSCARE-B continues to strengthen its R&D focus in the field of interventional treatment for structural heart disease. With a product portfolio covering tricuspid, aortic, and mitral valve diseases, the company has built a high-growth, comprehensive, and globally competitive core product matrix.
Guided by global clinical needs, the company is also optimizing the performance of existing products, accelerating the iteration and upgrade of core offerings, and actively exploring cutting-edge technologies and innovative pipelines. These efforts are driving the R&D and clinical translation of multiple new products, enriching the portfolio to meet diverse clinical needs and ensuring sustained momentum for long-term growth.